Clinical Trial in Vitamin D coming your way

C
O Connell K, Kelly S, Kinsella K, Jordan S, Kenny O, Murphy D, Heffernan E, O Laoide R, O Shea D, McKenna C, Cassidy L, Fletcher J, Walsh C, Brady J, McGuigan C, Tubridy N, Hutchinson M. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.Trials. 2013; 14(1):272. [Epub ahead of print]


BACKGROUND:There is increasing evidence linking vitamin D deficiency to both susceptibility to, and severity of, multiple sclerosis (MS). Patients with the clinically isolated syndrome represent the initial presentation of a demyelinating disorder, and those with asymptomatic lesions on magnetic resonance imaging (MRI) are at risk of progression to clinically definite MS. The aims of this study are to examine the immunologic effects of vitamin D in both healthy individuals and in patients with clinically isolated syndrome, and in the latter group the effects on disease progression assessed by MRI and clinical measures.
METHODS: This is a single-center double-blind randomized placebo-controlled clinical trial. The primary endpoint is the immunologic effects of two doses of vitamin D compared with placebo over 24 weeks in both healthy control participants and patients presenting with the clinically isolated syndrome. Healthy control participants (n = 39) and patients with clinically isolated syndrome (n = 45) will be randomized to one of three arms, namely 1) vitamin D 5,000 IU daily, 2) vitamin D 10,000 IU daily, or 3) placebo, and followed up for 24 weeks. In both patients and healthy control participants, the primary outcome will be immunologic measures of the frequency of CD4 T-cell subsets and cytokine responses in peripheral blood mononuclear cells, assessed at baseline, and after 16 and 24 weeks of treatment. Secondary endpoints, in the patients with clinically isolated syndrome, will be relapse activity, and the number of new T2 lesions and gadolinium-enhancing lesions assessed by MRI in the two vitamin D-treated groups compared with the placebo-treated group over the 24 weeks of the study.Trial registration: EU Clinical Trials Register: EudraCT: 2012-000635-68. ClinicalTrials.gov identifier: NCT01728922.
One of many trials I suspect


Smolders J, Peelen E, Thewissen M, Menheere P, Damoiseaux J, Hupperts R. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis. Mult Scler. 2013 Aug. [Epub ahead of print]

BACKGROUND:A low vitamin D status has been associated with multiple sclerosis (MS). Most circulating vitamin D metabolites are bound to vitamin D binding protein (DBP).
OBJECTIVES:The purpose of this study was to explore whether there is an association between MS and DBP.
METHODS:We compared DBP concentrations in blood samples of controls (n = 30) and subjects with relapsing-remitting MS (RRMS) during remission (n = 29) and relapse (n = 15). Furthermore, we explored correlations of DBP with 25- hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D levels (1,25(OH)2D), and the effect of high-dose vitamin D3 supplementation on DBP levels in RRMS patients (n = 15).
RESULTS: DBP-concentration did not differ between the sub-groups measured, and there was no correlation between DBP and vitamin D metabolite concentration within the physiological range. Upon supplementation of high doses vitamin D3, DBP concentration remained unaltered. After supplementation, serum 1,25(OH)2D(R = 0.517, p = 0.049), but not 25(OH)D, correlated positively with DBP.
CONCLUSIONS: We found no association between DBP, MS, and vitamin D status within the physiological range. After high – dose vitamin D supplementat
ion, DBP concentrations may be relevant for vitamin D metabolism.


Is the effect of vitamin D really in established MS or is the major activity concerned with development of MS in the firstplace?

About the author

MouseDoctor

7 comments

  • I just observed that my VitD levels diminished about 50% during a relapse in comparison to VitD levels during relapse-free time. Both levels were low but there is this different which I interpret as a disease activity marker. Question is if it indicative of MS activity or of inflammation in general (would be interesting to test eg Crohn's patients for their VitD levels).

  • Hot weather is known to be a problem with MS. It is difficult to function. This is probably more down to our body temperature rising than the sun. When we avoid the sun we deplete our vitamin D levels. It puzzles me as to why there is such a high incidence of MS is places like Sardinia. Is the sun the factor or something else responsible for the geographic likelihood of developing MS?

  • It occur as a result of a combination of environmental factors such as infectious agents and genetics, I don't remember that it is a cause of too much sun light, high population maybe 🙂

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives